HCGHealthcare

Healthcare Global Enterprises Limited

Hospital · ISIN INE075I01017 · BSE 539787 · NSE EQ · FV ₹10
Last price
₹687
+1.93%today
What this company does

Healthcare Global Enterprises Limited operates in Hospital, part of the Healthcare sector. It booked ₹695 cr of revenue in its latest quarter (Q1 FY27) and kept 2.0% of sales as profit.

Where precision meets compassion 35+ At HCG, we remain steadfast in our mission to redefine the standards of cancer care and specialty healthcare in Years of excellence inn India and beyond.
In the report:
38out of 100
Equitytale Health Score
Strained

Healthier than 38% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 33–150 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
47

At close. Not part of the score.

Profitability & returns20

How much profit it earns on the money it employs

Balance sheet10

How much it owes, and whether earnings cover the interest

Cash quality98

Whether reported profit actually arrives as cash · highest in its sector on what we could measure

Growth & consistency44

Whether sales and profit have grown, and how steadily

Valuation11

What today's price implies, against our models or its peers

Governance & risk79

How much of the promoters' stake is pledged, and how much they hold

Is this company doing well?
not investment advice
Strengths
Makes a profit
Sales up 13% vs last year
Profit up 190% vs last year
Promoters hold 64%
Turns profit into real cash
Watch-outs
! Thin 2.0% net margin
! 5.2% of promoter stake pledged
! Low 4.1% return on equity

What if I invest in HCG?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 0% a year, it would become
₹12.00 lakh

The slider starts at 0%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹687 +1.93%
latest close · 2026-09-17
1-year return
+210.3%
52-wk low ₹21552-wk high ₹775
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio186.7High
LowAverageHigh
P/B ratio7.70High
Below bookModerateHigh
EV / EBITDA19.8High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity4.1%Weak
WeakFairStrong ▸15%
Return on capital8.7%Fair
WeakFairStrong
Net margin2.0%Thin
ThinDecentStrong
EBITDA margin19.3%Decent
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.65Moderate
LowModerateHigh ▸1
Interest cover1.6×Risky
RiskyOkayStrong ▸5×
Current ratio1.09Healthy
Tight ◂1HealthyAmple
More figures
Market cap
₹10,259 cr
Book value
₹89
EPS
₹0.92
latest quarter
Net debt
₹374 cr
owes more than its cash
Enterprise value
₹10,634 cr
EBITDA
₹538 cr
annualised
EBIT
₹256 cr
annualised
Operating margin
9.2%
Return on assets
1.4%
Earnings yield
0.54%
P/S
3.69
Sales / share
₹186.2
Tax rate
35.6%
Face value
₹10
Shares
14.9 cr
Working capital
₹86 cr
Current assets
₹1,069 cr
Current liabilities
₹983 cr
Delivery %
55.8%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the FY 2025 report & filings
not investment advice
Hard to value confidentlyLow confidence
One year's profit is a one-off (far above the multi-year norm), so its recurring earnings power is unclear.
Models span ₹20₹51, midpoint ₹35

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹695 cr
Other Income₹12 cr
Total Income₹707 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹187 cr
Inventory Change (±)₹-8 cr
Employee Benefit Expense₹105 cr
Finance Costs₹40 cr
Depreciation & Amortisation₹70 cr
Other Expenses₹290 cr
Total Expenses₹683 cr
Profit before Tax₹24 cr
Tax Expense₹9 cr
Share of JV / Associates₹93 L
Net Profit₹16 cr
Net margin on total income2.3%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹179 cr25.2%
Employee benefit expense₹105 cr14.8%
Finance costs₹40 cr5.6%
Depreciation & amortisation₹70 cr9.9%
Other expenses₹290 cr40.9%
Tax expense₹9 cr1.2%
Profit for the period₹16 cr2.3%
Total income ₹707 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue633 cr652 cr695 cr
Total income636 cr665 cr707 cr
Expenses629 cr633 cr683 cr
Profit before tax-6 cr73 L24 cr
Tax2 cr-3 cr9 cr
Net profit (owners' share)-9 cr2 cr14 cr
Net margin (owners' share, on revenue)-1.5%0.3%2.0%
EPS (₹)-0.680.150.92
YoY (latest quarter): total income +14.1% · net profit +189.9%
Balance sheet & cash flow · as of Mar 2026
Moderate debt
Total assets
₹3,923 cr
Shareholder equity
₹1,332 cr
parent shareholders
Total debt
₹910 cr
Cash
₹536 cr
Cash flow · H1 FY26
Operating
₹192 cr
Investing
₹-58 cr
Financing
₹-81 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,769₹1.26 L cr54.3
Max Healthcare Institute Limited₹1,037₹1.01 L cr78.1
Manipal Health Enterprises Limited₹722₹85,125 cr92.0
Fortis Healthcare Limited₹886₹66,897 cr62.8
Aster DM Quality Care Limited₹761₹39,412 cr613.4
Global Health Limited₹1,424₹38,273 cr60.2
Narayana Hrudayalaya Ltd.₹1,869₹38,187 cr45.8
Krishna Institute of Medical Sciences Limited₹792₹33,258 cr190.3
Dr. Agarwal's Health Care Limited₹500₹15,855 cr87.4
Same industry · latest reported numbers · not a recommendation.
Corporate actions
ActionDetailEx-date
Rights issue17:12 Mar 2026
Who owns it · 2026-06-30
5.2% pledged
Promoter
64.2%
FII / Foreign
2.7%
DII / Domestic
19.2%
Retail / others
13.8%
Promoter stake down 7.1% over the last 12 quarters.
Smart-money activity
Insider trades
BoughtSunu Manuel · KMP38,799 · ₹2.8 cr13 Aug 26
SoldMadan Kumar Sampath · Designated Person34,970 · ₹2.5 cr10 Aug 26
SoldSunu Manuel · KMP27,000 · ₹1.9 cr10 Aug 26
Bulk / block deals
short · NSE163 Sep 26
short · NSE4124 Apr 26
short · NSE4830 Mar 26
Stake changes
SoldMotilal Oswal BSE Healthcare ETF→ 2.86% · 5.19 L4 May 26
BoughtMotilal Oswal Balanced Advantage Fund→ 5.04% · 1.55 L29 Oct 25
SoldAceso Company Pte. Ltd.→ 0.00% · 79.66 L11 Sep 25
Promoter pledges
PledgedHector Asia Holdings II Pte. Ltd. and KIA EBT II Scheme 10 · 3.56% held30 May 25
PledgedThe Hongkong and Shanghai Banking Corporation Limited, Singapore branch7.17 cr · 0.00% held30 May 25
PledgedBajaj Financial Securities Limited18.93 L · 2.20% held12 Mar 25
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Postal ballot · 21 Jan 2026
See the official result
1
APPROVAL OF THE VARIATIONS TO THE CONSULTANCY ARRANGEMENT WITH DR. B.S. AJAIKUMAR
Promoters had a personal stake in this
Backed by 94% of shareholders other than promotersneeded 50%
2.54 cr votes for, 17.32 L against · 6% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 7 named members
owning 64.2% between them · as of 2026-06-30
HECTOR ASIA HOLDINGS II PTE. LTD.54.27%
B S AJAIKUMAR9.30%
AAGNIKA AJAIKUMAR0.23%
ASMITHA AJAIKUMAR0.23%
CATALYST TRUSTEESHIP LIMITED0.18%
ANJALI AJAIKUMAR ROSSIno shares
BHAGYA A AJAIKUMARno shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹425 cr raised in Mar 2026 by offering new shares to existing shareholders

As of Jun 2026, the company says it has spent 100% of what it set aside, leaving ₹0.01 L still to be spent. Care Ratings Limited watches the spending on the exchange’s behalf.

Pre-payment and/ or repayment of all, or a portion of, certain outstanding borrowings availed by our Company and by one of our wholly owned Subsidiaries, HCG NCHRI Oncology LLP
100%
₹170 cr of ₹170 cr
Part-payment of consideration for acquisition of 34.00% additional stake in equity share capital of Vizag Hospital and Cancer Research Center Private Limited, one of our existing Subsidiaries
100%
₹154 cr of ₹154 cr
General corporate purposes*#
spent more than set aside
100%
₹96 cr of ₹96 cr
Issue related expenses**
95%
₹5 cr of ₹5 cr
Spent by quarter: 0%100% (to Jun 2026)

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.